Novo Nordisk gains edge as US approves weight loss pill

Novo Nordisk has secured a significant regulatory victory, following the United States Food and Drug Administration’s approval of its new weight loss pill containing semaglutide. The decision delivers the Danish pharmaceutical group a first-mover advantage in the fiercely competitive market for oral obesity treatments.

The new medication will be marketed under the Wegovy name, identical to Novo’s established injectable product. The oral formulation aims to address the demand for more convenient alternatives to injectable therapies, appealing to a broader patient base. Shares in Novo Nordisk rallied by 7.6 percent in Copenhagen after the news, reflecting renewed investor confidence, particularly as the business contends with increased competition and supply concerns that have pressured the stock throughout the year.

For months, Novo Nordisk had faced mounting challenges from Eli Lilly, its American rival, and from compounding pharmacies supplying discounted versions of weight loss medicines. Novo’s injectable Wegovy, launched in 2021, initially captured significant market share but subsequently lost momentum due to logistical bottlenecks and intensifying competition. Over the last year, the company’s share price has fallen 48 percent amid successive profit warnings and a boardroom reshuffle.

The FDA’s approval is expected to spur growth, with analysts projecting peak annual global sales of approximately 3.8 billion dollars for the pill in an obesity market that could reach 150 billion dollars within the next decade. The manufacturer has signalled readiness to commence distribution, anticipating a full commercial launch early next month. The oral semaglutide, previously available only as Rybelsus for diabetes management, will now be accessible for chronic weight management in adults classified as obese or overweight who have at least one associated health condition.

A pivotal clinical study conducted over 64 weeks demonstrated that trial participants taking 25 milligrams of the pill once daily experienced an average reduction in body weight of 16.6 percent, significantly exceeding the 2.7 percent observed in the placebo group. The results strengthen the case for oral therapeutics as effective long-term interventions for weight control.

While Novo Nordisk enjoys a first-mover position in the oral weight loss segment, this lead may be short-lived. Eli Lilly is poised to introduce its own pill version of Zepbound, after reporting positive late-stage trial outcomes, and has already submitted its data to regulatory authorities. Meanwhile, Pfizer has withdrawn from the race, discontinuing development of its investigational pill earlier in the year.

Novo Nordisk has also applied for marketing authorisation from the European Medicines Agency and other regulatory bodies. Senior leadership has expressed optimism that the updated product line, comprising both injectable and oral options, will enable the company to meet burgeoning demand in key international markets.